Popular terms

Allergy topics
Autoimmune
Prophylactic
Ophthalmic
Autoimmune Disorder
Immune Disorder
Dermatitis
Staurosporin
Aspergillosis
Angioedema
Allergic Rhinitis
Food Allergy
Therapeutical
Bronchopulmonary
Staurosporine
Sudden Infant Death

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Allergy patents



      

This page is updated frequently with new Allergy-related patent applications.




Date/App# patent app List of recent Allergy-related patents
04/07/16
20160095448 
Breathable mattress pad and sleeping accessories
Sleeping accessories such as mattress pads, mattress topper covers, and sheet savers are disclosed herein comprising integrated padded mesh material. Integrated padded mesh material, when used in the sleeping accessories, results in improved air flow for the user, which can reduce complications during sleep such as sudden infant death syndrome.
Breathablebaby, Llc


03/24/16
20160083466 
Anti-il-25 antibodies and uses thereof
The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity.
Regeneron Pharmaceuticals, Inc.


03/24/16
20160082101 
Horse allergen and methods
A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of ige antibodies specifically binding to the horse allergen, wherein the presence of such ige antibodies specifically binding to the horse allergen is indicative of type 1 allergy. A method for treatment of type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its ige binding response.
Phadia Ab


03/10/16
20160069858 
Rapid allergy testing method
The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient.

03/03/16
20160060367 
Refined product obtained from rice hull and preparation process and use thereof
Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type ii arabinogalactan having a number average molecular weight in the range of 56 to 103 kda. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer..
China Medical University


02/25/16
20160053270 
Rnai-mediated inhibition of histamine receptor h1-related conditions
Rna interference is provided for inhibition of histamine receptor h1 mrna expression, in particular, for treating patients having an hrh1-related condition or at risk of developing an hrh1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.. .
Arrowhead Research Corporation


02/25/16
20160051666 
Novel prostate kallikrein allergen
Methods for treatment of a type i allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of seq id no: 1 or the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its ige binding response. Diagnostic kits comprise the polypeptide of seq id no: 1 or the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, immobilized on a solid support..
Phadia Ab


02/25/16
20160051417 
Urine detection inductor suitable for large-scale production
A detector for wet diaper is suitable for large-scale production. The detector comprises a nonwoven fabric (1) and at least two electrodes (2, 3) which are carbon powder coated on the nonwoven fabric (1).

02/04/16
20160030554 
Tolerogenic synthetic nanocarriers for allergy therapy
Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and mhc class ii-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.. .
Selecta Biosciences, Inc.


01/28/16
20160022539 
A prefilled medication device, making and using the same
The invention generally relates to prefilled disposable medication devices, method of making, and using to store, contain and deliver at least a diluent for allergenic extract and more particularly to a prefilled cartridge containing a diluent for allergenic extract for use with an injection pen for allergy treatments.. .
Phd Preventive Health Care And Diagnostics, Inc.


01/21/16
20160015821 

Glycotargeting therapeutics


Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .
Anokion Sa


01/21/16
20160015794 

Topical ocular preparation of botulinum toxin for use in ocular surface disease


A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation.
Botulinum Toxin Research Associates, Inc.


01/21/16
20160015630 

Sprayable oxygenated saline composition and treating nasal congestion, allergy, dryness, eye irritation, throat irritation, wounds, and skin as applied to human tissues


An oxygenated saline composition is provided comprising stabilized oxygen, sodium chloride (aqueous saline solution), and optionally one or more homeopathic components. The stabilized oxygen can include quad-atomic oxygen.
Oxy Bump Corporation


12/03/15
20150344934 

Novel high throughput assay for finding new jak3 interacting compounds, biomolecules, and inhibitors.


Janus kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of jak3 was associated with human hematologic and epithelial malignancies.

12/03/15
20150344908 

Method of genetically altering and producing allergy free cats


A transgenic cat with a phenotype characterized by the substantial absence of the major cat allergen, fel d i. The phenotype is conferred in the transgenic cat by disrupting the coding sequence of the target gene with a specialized construct.

12/03/15
20150342514 

System and multiple allergen testing


The testing apparatus includes a capsule 108 tray and a hand held allergen applicator 104 that facilitates convenient storage and easy application of such allergens simultaneously. The hand held applicator 104 includes a plurality of prongs to administer the respective plurality allergen under the skin of the patient.

11/26/15
20150335735 

Peptide carrier fusion proteins as allergy vaccines


The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the n- and c-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.. .
Biomay Ag


11/19/15
20150329864 

Design of oligonucleotide analogs as therapeutic agents


It is believed that the compounds and compositions as described herein have therapeutic utility against a variety of diseases, including viral diseases, autoimmune diseases (such as, allergy, asthma, and inflammatory disorders) and cancer.. .

11/19/15
20150329624 

Igy composition for use in celiac disease


The present invention relates to an igy composition characterized in that said igy composition contains igy antibodies, fragments, and/or fab fragments thereof that specifically bind to a peptide with the amino acid sequence of seq id no: 1 and to the use of this igy composition in the therapy of celiac disease, rheumatism, and/or wheat allergy.. .
Charite - Universitatsmedizin Berlin


11/19/15
20150328294 

Novel immunotherapeutic molecules and uses thereof


The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with t lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with t cells in subjects having an allergy to the ara h 1 allergen.
Health, Alfred


11/19/15
20150327576 

Animal food composition and process for production


An animal food composition comprising a protein source and corn starch, wherein native high-amylose corn starch comprises at least 50% of the corn starch. The composition can be used to treat or prevent a food allergy in an animal.
Hill's Pet Nutrition, Inc.


10/29/15
20150306211 

Process for producing an allergen extract


The present invention discloses processes for producing native, depigmented and polymerised allergen extracts. The invention further discloses extracts produced via the processes, and pharmaceutical and vaccine compositions comprising the extracts, for diagnosis and treatment of allergy..
Laboratorios Leti, S.l.


10/29/15
20150306146 

Methods of treating or preventing respiratory conditions


The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an ige-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .
Mesoblast, Inc.


10/22/15
20150299294 

New fusion proteins for the treatment of allergic diseases


The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the targeting unit is a fgl-2 c-terminal peptide according to seq id no 1. Provided herein are also uses of said fusion protein as a vaccine for treating allergy, such as shrimp, peanut or mite allergy, as well as a vaccine composition and methods for producing such fusion proteins..
Veteriaerinstituttet


10/22/15
20150297703 

Bifidobacterium for dust mite allergy


A composition comprising bifidobacterium breve for use in improving lung function in human subjects suffering from dust mite allergy.. .
N.v. Nutricia


10/22/15
20150297641 

Allergy treatment using acid treated aqueous whey protein extract


The invention relates to manufacture of whey protein extracts, to infant formula and to reducing or preventing food allergy. The whey protein extract is produced from a whey protein-containing composition by contacting a whey protein-containing composition with an aqueous solution to form a sample including a soluble protein-containing component and an insoluble component; recovering the soluble protein-containing component from the sample; and acidifying the soluble protein-containing component, thereby producing the whey protein extract.
Women's And Children's Health Research Institute


10/22/15
20150297129 

System and automatic reading of an allergy


A system and method for automatic reading skin for an allergy to a substance, includes a consumer electronics device that acquires images of skin; a consumable member having a surface divided into elementary areas, each elementary area with a different possible allergenic substance; and a palette that, when applied against each elementary area brings the depositing part into contact with the skin thereby depositing the corresponding possible allergenic substance on or under the skin, where an image processing operation of the image of the skin taken by the consumer electronics device localizes the location that each depositing part has deposited the possible allergenic substance during the application and provides information in relation with a sensitivity of the skin, as indicated by a visible reaction, to the possible allergenic substance at each localized location.. .
Ergylink


10/15/15
20150289794 

Allergy skin test applicator, and related testing tray, testing kit and testing method


An allergy testing kit contains a plurality of allergy testing applicators, an allergy testing tray and a plurality of allergen bottles each containing an allergen. Each of the applicators contains an elongated handle, a plurality of arms extending from the elongated handle and disposed in an asymmetrical configuration, and a plurality of legs with tines extending from each of the arms.

10/01/15
20150276757 

Wheat proteomic microarray for biomarker discovery


This invention pertains to the preparation of arrays containing the proteome of wheat, including gluten and non-gluten proteins. Antibodies to wheat gluten have been shown to be elevated, not only in celiac disease and wheat allergy, but also in neuropsychiatric disorders, such as schizophrenia, bipolar disorder, and autism.
The Trustees Of Columbia University In The City Of New York


10/01/15
20150273115 

M cells and artificial skin sheet


[problem] to provide m cells having excellent strength and anti-allergy activity and an artificial skin sheet formed from the m cells. [solution] gp2 contained in the m cells is transferred to the intracellular tight junction and galectin 9 is expressed in the m cells.

09/24/15
20150265198 

Plastic blood lancet


The present invention provides a surgically invasive pointed article for skin penetration and capillary whole blood extraction whose penetration ability can be disabled after use by deforming the tips. The present invention is made by injection moulding a plastic needle 35 having an anchoring means 45 using a first material, followed by another injection moulding process to over-mould a first body segment 20 and second body segment 30 using a second material to encase the plastic needle 35 thereby anchoring the plastic needle 35 to prevent further movement of the plastic needle 35.

09/10/15
20150250870 

Compositions for immunotherapy


The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals suffering from a peanut allergy. The present invention further relates to the use of the present compositions for the treatment of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment for desentizing the immune system of a mammal for an allergen.
Hal Allergy Holding B.v.


09/10/15
20150250220 

Nutritional compositions containing ceramide and uses thereof


The present disclosure relates to nutritional compositions that include at least one ceramide. The nutritional compositions may further include galactose, sialic acid, or cholesterol.
Mead Johnson Nutrition Company


09/03/15
20150246889 

Benzimidazole derivatives as pi3 kinase inhibitors


This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
Glaxosmithkline Llc


08/27/15
20150239886 

Substituted fused tricyclic compounds, compositions, and medicinal applications thereof


The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity. Such conditions include, but not limited to, arthritis, alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, t-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, t-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or type i diabetes, complications from diabetes, rheumatoid arthritis, asthma, crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis.

08/27/15
20150238581 

Novel histamine releaser contained in human sweat


Provided arc a sweat allergy antigen, an antibody capable of binding to the antigen specifically, and others, which are produced utilizing a microorganism-originated protein that exists in sweat allergy patient in a dissolved state or a partial peptide of the protein.. .
Hiroshima University


08/20/15
20150231234 

Use of anti-cd1 antibodies for the modulation of immune responses


The invention provides methods for the administration of an anti-cd1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.. .
Beth Israel Deaconess Medical Center, Inc.


08/13/15
20150225398 

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224199 

Pharmaceutical compositions for the treatment of inflammatory disorders


Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

08/13/15
20150224153 

Probiotics for use in reducing eosinophilia and respiratory allergies


The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms..
Dupont Nutrition Biosciences Aps


08/06/15
20150218563 

Compositions and methods for modulation of rorgammat functions


The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

08/06/15
20150218215 

Cladosporium peptides


Polypeptides which may be used for preventing or treating allergy to moulds of the cladosporium and/or alternaria genus, have up to 30 amino acids in length and comprise: (i) the amino acid sequence: (a) ggykaavrptmle (seq id no: 35; cla35), (b) ae v yqklk sltkk (seq id no: 31; cla16), (c) vaityasraqgae (seq id no: 32; cla25), (d) ghhfkergt-gslvit (seq id no: 33; cla26), or (e) anytqtktvsirl (seq id no: 34; cla29); or (ii) a t cell epitope-containing variant sequence which is a said amino acid sequence (i) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.. .
Circassia Limited


08/06/15
20150216470 

Allergy testing device and testing for allergies


An allergy testing system comprises a skin test device having a grip portion for holding the device. One or more legs extend from the grip, and each leg is oriented to interact with a well containing a potential allergen.
Lincoln Diagnostics, Inc.


07/30/15
20150212097 

Monoclonal lge antibody that binds to sweat allergy antigen protein


Provided include a human ige antibody that binds to a sweat allergy antigen protein and a human high-affinity ige receptor but does not induce degranulation in a reaction with the sweat allergy antigen protein, and a composition for treatment or diagnosis of sweat allergy comprising the same.. .
Hiroshima University


07/30/15
20150210742 

Novel allergen from ragweed pollen and uses thereof


The present invention notably concerns a novel major allergen from ragweed pollen, named amb a x, as well as isoallergens and isoforms thereof. Fragments of the aforementioned polypeptides and homologous polypeptides, in particular homologous polypeptides in related plant species, also make part of the invention.
Stallergenes S.a.


07/30/15
20150209410 

Compositions and methods relating to the treatment of diseases


A method is provided for the treatment and/or prophylaxis of a condition where an enhancement of a th1-mediated immune response and suppression of a th2/th17-mediated immune response are desired. The method comprises the step of administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from ifn-α10, ifn-α14, and a hybrid thereof.
Alfacyte, Ltd.


07/23/15
20150203537 

Inhibition of gliadin peptides


Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


07/16/15
20150196635 

Peptides for vaccine against birch allergy


The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.. .
Circassia Limited


07/16/15
20150196633 

Hypo-allergenic cross-linked proteins for use in the prevention of an allergy against milk-proteins and for use in the induction of oral tolerance


The present invention provides a hypo-allergenic cross-linked protein for use in the prevention of an allergy against milk proteins, or for use in the induction of oral tolerance for milk proteins, said cross-linked protein being selected from cross-linked casein, cross-linked caseinate and combinations thereof. The invention further provides a nutritional composition for use in the prevention of an allergy against milk proteins or for use in the induction of oral tolerance against milk proteins..
Friesland Brands B.v.


07/02/15
20150183848 

Treatment of lge-mediated disease


The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble cd23 (scd23) that binds and sequesters ige. Thus, the scd23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased ige levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers..
Trustees Of Boston University


06/25/15
20150175710 

Alpha-enolase specific antibodies and use in immune diseases


A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology


06/25/15
20150174225 

Nanoparticles for treatment of allergy


The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions.
Allertein Therapeutics, Llc


06/11/15
20150158874 

Novel pyridopyrimidine derivatives and use thereof


The invention provides novel substituted pyridopyrimidines represented by formula i or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ oh kinase family (pi3k) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders..
Cmg Pharmaceutical Co., Ltd.


06/04/15
20150153358 

Materials and methods for diagnosing and treating shellfish allergy


The disclosure provides materials and methods for diagnosing, treating and preventing shellfish allergic reactions, including allergic reactions to shrimp. The technology involves one or more shellfish-specific proteins selected from the group of myosin light chain, sarcoplasmic calcium-binding protein, hemocyanin, fatty acid binding protein, and troponin c, for example from shrimp, as well as encoding polynucleotides, vectors host cells, and specific binding partners for such proteins, e.g., antibodies.
Icahn School Of Medicine At Mount Sinai


06/04/15
20150152148 

Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies


The present invention refers to recombinant and molecules coding to hybrids polypeptides of different allergens from d. Pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites.
Bial Industrial Farmaceutica, S.a.


06/04/15
20150152138 

Uses of kappa opioid synthetic peptide amides


The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.


06/04/15
20150150926 

Composite with antibacterial and antipruritic functions


A composite with antibacterial and antipruritic functions includes a first substrate extracted from a plant, a second substrate and a base, and the first substrate includes a loniceraiaponica extract and an acanthopanax extract, and both loniceraiaponica extract and acanthopanax extract have a weight percentage ranging from 0.75 to 1.33, and the composite can effectively restrain the itch caused by skin pustules, folliculitis, and mosquito bites, and achieve the moisturization and antipruritic and anti-dander effects for mitigating the symptoms caused by candida albicans and staphylococcus aureus. In addition, this composite has good effects on general skin diseases such as hand eczema (ktpp), eczema, and lip herpes.
Li Tzu Pao Mei Regiman Beauty Public Ltd. Company


06/04/15
20150150925 

Wound healing composite with a function of promoting the growth of granulation tissues


A composite with antibacterial and antipruritic functions includes a first substrate extracted from a plant, a second substrate and a base, and the first substrate includes a loniceraiaponica extract and an acanthopanax extract, and both loniceraiaponica extract and acanthopanax extract have a weight percentage ranging from 0.75 to 1.33, and the composite can effectively restrain the itch caused by skin pustules, folliculitis, and mosquito bites, and achieve the moisturization and antipruritic and anti-dander effects for mitigating the symptoms caused by candida albicans and staphylococcus aureus. In addition, this composite has good effects on general skin diseases such as hand eczema (ktpp), eczema, and lip herpes.
Li Tzu Pao Mei Regiman Beauty Public Ltd. Company


06/04/15
20150150924 

Wound healing composite with a function of promoting the growth of granulation tissues


A wound healing composite with a function of promoting the growth of granulation tissues includes a substrate extracted from a plant and a base, and the substrate includes a loniceraiaponica extract, a mugwort extract, and ginkgo, and both loniceraiaponica extract and ginkgo have a weight percentage ranging from 0.28% to 3.5%. The wound healing composite can effectively promote the growth of granulation tissues, and loniceraiaponica, mugwort, ginkgo and other ingredients are extracts of natural plants, and thus the wound healing composite has a low drug resistance and does not have the side effect of drug allergy or the doubt leading to skin cancer..
Li Tzu Pao Mei Regiman Beauty Public Ltd. Company


05/28/15
20150149230 

Playdate scheduling system


A social scheduling system includes member profile information. Each member profile includes information about a member and one or more of the member's associated entities.

05/28/15
20150148361 

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv


05/21/15
20150140140 

Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care


The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (cox) and lipoxygenase (lox) enzymatic activity in normal, aged and damaged dermal cells and tissues.
Unigen, Inc.


05/21/15
20150140137 

Combined allergy treatment and anti-drying compositions and related methods


Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy treatment composition or another anti-mucosal composition. In some embodiments and implementations, a composition may be provided comprising an allergy treatment composition comprising an antihistamine in a therapeutically effective amount for treating the allergy condition in the human having the allergy condition.
Xlear, Inc.


05/21/15
20150140012 

Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis


The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions..
Nuvo Research Ag


05/14/15
20150133533 

Compositions and methods for the treatment of cough


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

05/07/15
20150126898 

Fully self-contained unit dose devices for allergy skin testing


The present invention discloses a system for applying antigens or other diagnostic substances to the skin of a subject for allergy testing. The system is comprised of fully contained predetermined quantities of antigenic or other testing material contained in sealed unit doses that maintain sterility and provide for precise handling and administration.
Mystic Pharmaceuticals, Inc.


05/07/15
20150126593 

Compositions and methods for the treatment of asthma and allergy


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of asthma and allergy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

05/07/15
20150126459 

Plant profilin polypeptides for use in non-specific allergy immunotherapy


The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. Grass or tree pollen) by bystander suppression with a plant profilin (e.g.
Alk-abello A/s


04/30/15
20150118264 

Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen


The present invention is directed to a pharmaceutical composition including (e.g. For use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh


04/30/15
20150118183 

Negatively charged nucleic acid comprising complexes for immunostimulation


The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. Peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh


04/30/15
20150116485 

Device to shade persons from bright sunshine, dynamically from large height by matching shade pattern to presence


A device, system and method of shading person large open area from large height without obstruction to view, work and play by matching shade pattern formed by shading unit for the given sun position and the location of the person on land and building, by means of shading units moved by control from computer and by manual control and providing local cooling by directed, pulsed cold air jet. Shading unit supported by cables and at periphery shading unit on cantilever based support is used and for small areas.

04/09/15
20150098969 

Alternaria peptides


Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the alternaria and/or cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of wswkigpaiatgnt (alt28; seq id no: 101) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b) a polypeptide comprising the amino acid sequence of kyrrvvragvkvaqtar (alt34a; seq id no: 107) or a t cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of kyagvfvstgtlggg (seq id no: 112) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d) a polypeptide comprising the amino acid sequence of aevyqklkalakktygq (alt13a; seq id no: 83) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e) a polypeptide comprising the amino acid sequence of slgfnikatnggtld (alt01a; seq id no: 60) or a t cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of sakrmkvafkldiek (alt06; seq id no: 72) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g) a polypeptide comprising the amino acid sequence of dityvatatlpnycr (seq id no: 111) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; and (h) a polypeptide comprising the amino acid sequence of gwgvmvshrsget (alt14; seq id no: 84) or a t cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a t cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide is up to 30 amino acids in length.. .
Circassia Limited


04/09/15
20150098952 

Novel therapeutic target and diagnostic marker for asthma and related conditions


Cd48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. Cd48 is thus presented as a target molecule in the treatment of said conditions.
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd


03/26/15
20150087697 

Compositions and methods for the treatment of muscle pain


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

03/26/15
20150086594 

Anti-allergic medicament


The present disclosure relates to a method for the treatment of allergic conditions. In said method the allergens to which an individual is susceptible is identified as per the allergy profile and accordingly a formulation having potentized dispersions of each of the identified allergens is administered to the individual for a predetermined period and at a predetermined potency.

03/26/15
20150086593 

Allergy inhibitor compositions and kits and methods of using the same


Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed..

03/19/15
20150079173 

Formulations decreasing particle exhalation


Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, sars, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier.
Pulmatrix, Inc.


03/19/15
20150079155 

Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood


This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, t-lymphocytes, b-lymphocytes and/or nk cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy.. .
Danmarks Tekniske Universitet


03/12/15
20150074237 

Method for controlling information terminal apparatus


A control method causes a computer of an information terminal apparatus to perform a process including: receiving, from a first server, first display data causing a user of the information terminal apparatus to confirm the purpose of use of recipe information and asking for the permission to collect the recipe information; accessing a second server and receiving selected recipe information and control data for a cooker for preparation based on the selected recipe information; and when it is selected to permit collecting the recipe information for a purpose of use related to health care, and it is determined that selected recipe information corresponding to the set control data has an identifier indicating that the recipe is for food related to a specific constitution, disorder, disease, or allergy, transmitting the selected recipe information with the identifier, in association with a user id of the information terminal apparatus, to the first server.. .
Panasonic Intellectual Property Corporation Of America


03/05/15
20150065450 

Compound of glycosaminoglycan and its preparation method as well as application


The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (ha), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the cd44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug..
Holy Stone Healthcare Co., Ltd.


03/05/15
20150065446 

Compound of glycosaminoglycan and its fabrication method as well as application


The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (ha), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the cd44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug..
Holy Stone Healthcare Co., Ltd.




Allergy topics: Autoimmune, Prophylactic, Ophthalmic, Autoimmune Disorder, Immune Disorder, Dermatitis, Staurosporin, Aspergillosis, Angioedema, Allergic Rhinitis, Food Allergy, Therapeutical, Bronchopulmonary, Staurosporine, Sudden Infant Death

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Allergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergy with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3251

4512

0 - 1 - 102